Attached files
| file | filename |
|---|---|
| 8-K - CURRENT REPORT - Cellular Biomedicine Group, Inc. | cbmg_8k.htm |
Exhibit 99.1
Thermo Fisher Scientific and Cellular
Biomedicine Group Announce Strategic Partnership
to Develop Manufacturing Processes
SHANGHAI, China and CUPERTINO, Calif., November 06,
2017 /GlobeNewswire/ — Cellular Biomedicine Group
Inc. (NASDAQ: CBMG) (“CBMG” or the
“Company”), a leading clinical-stage biopharmaceutical firm engaged in
the development of immunotherapies for cancer and effective stem
cell therapies for degenerative diseases, today announced the
establishment of a strategic partnership with Thermo Fisher
Scientific (China) Ltd. (Thermo Fisher) to build a joint Cell
Therapy Technology Innovation and Application Center (Center) at
CBMG’s newly opened Shanghai Zhangjiang GMP facility. The
Center is named “CBMG-Thermo Fisher Scientific
Joint Innovation & Application
Center”. The partnership focuses on the research and
development of an automated cell therapy manufacturing
system.
“Break-through cell therapy technology such as CAR-T provides
unprecedented medical needs to cancer patients, yet the successful
commercialization of this technology will require robust logistics,
manufacturing and complex management systems,” commented Tony
(Bizuo) Liu, CEO of CBMG. “When we combine Thermo Fisher's
strengths in biopharmaceutical products and manufacturing quality
control processes with CBMG’s vertically integrated cell
therapy manufacturing system, we believe we can further increase
productivity, reduce cost, improve batch stability, reduce
variability and institutionalize the Chemistry, Manufacturing, and
Controls (CMC) processes, which we believe will help to address
some of the primary logistical challenges faced by the CAR-T cell
therapy industry. We are optimistic that this partnership will not
only bring mutual benefit to CBMG and Thermo Fisher, but also to
the cell therapy industry sector as a whole.”
“This cooperation demonstrates our commitment to China. As a
world leader in serving science, Thermo Fisher seeks to provide
total solutions for cell therapy research, development, and
manufacturing. We believe this will help to accelerate the
development of the cell therapy industry in China. Based on our
broad product portfolio, Thermo Fisher has developed outstanding
capabilities in global CAR-T manufacturing, including our Cell
Therapy Systems (CTS™) Dynabeads™ technology in the
first FDA-approved cell therapy.” said Gianluca Pettiti,
President of Thermo Fisher China, “We look forward to this
strategic partnership and the benefits that the Joint Innovation
and Application Center will provide to a vast Chinese patient
population.”
CBMG’s new Zhangjiang facility, together with an expanded
Wuxi and Beijing GMP facilities combined, comprises 70,000 square
feet for development and production. This will enable CBMG to
conduct simultaneous clinical trials for multiple CAR-T and stem
cell product candidates. At full production volumes, these
facilities could support treating 10,000 cancer patients and 10,000
Knee Osteoarthritis patients per year. The Company’s combined
GMP expansion will enable scaled-up supply for current and future
CAR-T clinical trials and streamline efficiency from R&D into
manufacturing of CAR-T cells for clinical use, IND filings and
future commercialization. The Company currently has ongoing CAR-T
Phase I clinical trials in China; CARD-1 for Diffuse Large B-cell
Lymphoma (DLBCL) and Non-Hodgkin Lymphoma (NHL) and CALL-1 for
adult Acute Lymphoblastic Leukemia (ALL), utilizing CBMG’s
proprietary and optimized CD19 construct.
Tony Liu, CBMG CEO and Gianluca Pettiti, Thermo Fisher Scientific
President, China sign strategic partnership; leaders witness the
moment together
|
CBMG and Thermo Fisher Scientific unveil signage for their new
Joint Innovation Application Center
|
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. develops proprietary cell
therapies for the treatment of cancer and degenerative diseases. We
conduct immuno-oncology and stem cell clinical trials in China
using products from our integrated GMP laboratory. Our GMP
facilities in China, consisting of twelve independent cell
production lines, are designed and managed according to both China
and U.S. GMP standards. To learn more about CBMG, please visit
www.cellbiomedgroup.com.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the
world leader in serving science, with revenues of more than $20
billion and approximately 65,000 employees globally. Our mission is
to enable our customers to make the world healthier, cleaner and
safer. We help our customers accelerate life sciences research,
solve complex analytical challenges, improve patient diagnostics,
deliver medicines to market and increase laboratory productivity.
Through our premier brands – Thermo Scientific, Applied
Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services
– we offer an unmatched combination of innovative
technologies, purchasing convenience and comprehensive services.
For more information, please visit www.thermofisher.com.
About Thermo Fisher Scientific China
Thermo Fisher Scientific (China) Co.,
Ltd has been operating in China for over 35 years. Headquartered in
Shanghai, Thermo Fisher Scientific China has branch offices in
Beijing, Guangzhou, Hong Kong, Chengdu, Shenyang, Xian, Nanjing,
Wuhan, Kunming and other cities with around 4,000 employees. Our
products mainly include analytical instruments, laboratory
equipment, chemical reagents, consumables, software and more;
providing comprehensive laboratory solutions and serving customers
across various industries. In order to meet the local needs in
China, we have established 6 manufacturing sites in Shanghai,
Beijing and Suzhou respectively. We also have 5 application centers
across the country, which bring world-class technology and products
with application development and training services to local
customers. Lastly, we have the China Innovation Center in Shanghai,
which develops products according to local demands with global
advanced technology. We have a nationwide maintenance network and
China service training team, including over 2,000 professionals
directly providing services for customers. We are committed to
enabling our customers to make the world healthier, cleaner and
safer. For more information, please visit www.thermofisher.com.
Forward-Looking Statements
This press release contains forward-looking
statements—including descriptions of plans, strategies,
trends, specific activities, investments and other non-historical
facts—as defined by the Private Securities Litigation Reform
Act of 1995, Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
Forward-looking information is inherently uncertain, and actual
results could differ materially from those anticipated due to a
number of factors, which include risks inherent in doing business,
trends affecting the global economy (including the devaluation of
the RMB by China in August 2015), and other risks detailed in
CBMG’s reports filed with the Securities and Exchange
Commission, quarterly reports on form 10-Q, current reports on form
8-K and annual reports on form 10-K. Forward-looking statements may
be identified by terms such as “may,”
“will,” “expects,” “plans,”
“intends,” “estimates,”
“potential,” “continue” or similar terms or
their negations. Although CBMG believes the expectations reflected
in the forward-looking statements are reasonable, they cannot
guarantee that future results, levels of activity, performance or
achievements will be obtained. CBMG does not have any obligation to
update these forward-looking statements other than as required by
law.
Contacts:
Sarah Kelly
Director of Corporate Communications, CBMG
+1 650 566-5064
+86 21 5406 9990
sarah.kelly@cellbiomedgroup.com